Metraipolis › archive › dc_61ff0741a391

Sodium-glucose cotransporter 2 inhibitors in breast cancer patients on endocrine therapy: a targeted strategy to mitigate long-term cardiometabolic risk — Europe PMC PMID:42332771

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42332771
DOI
10.1186/s12967-[numero omesso]-8
License (as archived)
solo-consultazione
Archived
2026-10-19T06:38:05.667Z
SHA-256 of the archived text
8f62c4d52cbcdec9b2d9d6e4f7eb28f5a924d0a14c11c04438b3806da6b6530f
Stable URL of this page
https://metraipolis.com/documento/dc_61ff0741a391

How to cite

Sodium-glucose cotransporter 2 inhibitors in breast cancer patients on endocrine therapy: a targeted strategy to mitigate long-term cardiometabolic risk — Europe PMC PMID:42332771 — Europe PMC (en), https://europepmc.org/article/MED/42332771 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_61ff0741a391 (Metraipolis archive dc_61ff0741a391, sha256 8f62c4d52cbcdec9b2d9d6e4f7eb28f5a924d0a14c11c04438b3806da6b6530f)
BibTeX
@misc{dc61ff0741a391,
  title = {Sodium-glucose cotransporter 2 inhibitors in breast cancer patients on endocrine therapy: a targeted strategy to mitigate long-term cardiometabolic risk — Europe PMC PMID:42332771},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42332771},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_61ff0741a391; sha256 8f62c4d52cbcdec9b2d9d6e4f7eb28f5a924d0a14c11c04438b3806da6b6530f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42332771. Agents can read the archived copy with the MCP tool read_document.